CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

Global pharma giant Eli Lilly plans to launch its diabetes and obesity treatment, tirzepatide, marketed under the brands ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk's (NYSE: NVO) stock crashed ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

California’s Medicaid program spent the most of all states on GLP-1 coverage, exceeding $1.4 billion, or $118 per enrollee.

Mounjaro (generic name Tirzepatide), developed by Eli Lilly, is an injectable medication aimed at managing type 2 diabetes ...

Elon Musk has admitted to taking a weight-loss drug in a Christmas Day post on X, formerly Twitter, as he shared a picture of ...

A Kenosha County jury has found Monroe Mitchell III, the pastor of Agape Love Christian Ministries, Inc. not guilty of sexual ...

The FDA also recommends that prescribed users reduce their caloric intake and increase their exercise The weight loss drug ...

The burgeoning demand for innovative drug delivery systems to address diverse diseases is identified as a primary catalyst ...